

Cohort Profile

Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations

Anna Bára Unnarsdóttir ^{1†}, Anikó Lovik^{2†}, Chloe Fawns-Ritchie^{3,4†}, Helga Ask^{5†}, Kadri Kõiv^{6†}, Kristen Hagen^{7†}, Maria Didriksen ^{8†}, Lea Arregui Nordahl Christoffersen^{9†}, Alexander Berg Garðarsson,¹ Andrew McIntosh,¹⁰ Anna K Kähler,¹¹ Archie Campbell ^{4,12}, Arna Hauksdóttir,¹ Christian Erikstrup ¹³, Dorte Helenius Mikkelsen,⁹ Drew Altschul ³, Edda Bjork Thordardottir,¹ Emma Maria Frans,¹¹ Gerd Kvale,^{14,15} Gunnar Tómasson,^{1,16} Hanna Maria Kariis,⁶ Harpa Lind Jónsdóttir,^{1,17} Harpa Rúnarsdóttir,¹ Ingibjörg Magnúsdóttir,¹ Jarle Eid,¹⁸ Jóhanna Jakobsdóttir,¹ Kaspar René Nielsen,¹⁹ Kathrine Agergård Kaspersen,^{13,20} Lili Milani,⁶ Lill-Iren Schou Trogstad,²¹ Lu Yi,¹¹ Mie Topholm Bruun,²² Patrick F Sullivan,^{11,23} Per Minor Magnus,²⁴ Qing Shen ¹¹, Ragnar Nesvåg,⁵ Ragnhild E Brandlistuen ^{25,26}, Reedik Mägi,⁶ Sisse Rye Ostrowski,^{8,27} Solveig Løkhammer,²⁸ Stian Solem,^{14,29} Ted Reichborn-Kjennerud,^{5,30} Thomas Folkmann Hansen,^{31,32} Thomas Werge,⁹ Thor Aspelund ^{1,33}, David J Porteous,^{4,12†} Fang Fang ^{2†}, Kelli Lehto,^{6†} Ole A Andreassen,^{34,35†} Ole Birger Vesterager Pedersen,^{36†} Stephanie Le Hellard^{14,28†} Unnur A Valdimarsdóttir^{1,11,37*†}

¹Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ²Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ³Department of Psychology, University of Edinburgh, Edinburgh, UK; ⁴Centre for Genomic and Experimental Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK; ⁵Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway; ⁶Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia; ⁷Department of Psychiatry, Molde Hospital, Møre og Romsdal Hospital Trust, Molde, Norway; ⁸Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; ⁹Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; ¹⁰Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK; ¹¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ¹²Centre for Medical Informatics, Usher Institute, Edinburgh, UK; ¹³Department of Clinical Immunology, Aarhus University Hospital, Aarhus N, Denmark; ¹⁴BCBP, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway; ¹⁵Department of Clinical Psychology, University of Bergen, Bergen, Norway; ¹⁶Department of Rheumatology, University Hospital, Iceland; ¹⁷Faculty of Psychology, School of Health Sciences, University of Iceland, Reykjavik, Iceland; ¹⁸Faculty of Psychology, Center for Crisis

Psychology, University of Bergen, Bergen, Norway; ¹⁹Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark; ²⁰Danish Big Data Centre for Environment and Health (BERTHA), Aarhus University, Roskilde, Denmark; ²¹Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway; ²²Department of Clinical Immunology, Odense University Hospital, Odense, Denmark; ²³Departments of Genetics and Psychiatry, University of North Carolina, NC, USA; ²⁴Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway; ²⁵Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway; ²⁶Norwegian Mother, Father and Child Cohort Study (MoBa), Norwegian Institute of Public Health, Oslo, Norway; ²⁷Department Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; ²⁸NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; ²⁹Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway; ³⁰Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ³¹Danish Headache Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark; ³²NovoNordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark; ³³Icelandic Heart Association, Kopavogur, Iceland; ³⁴Faculty of Medicine, NORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ³⁵Faculty of Medicine, NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; ³⁶Department of Clinical Immunology, Zealand University Hospital, Denmark; and ³⁷Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*Corresponding author. Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Sturlugata 8, 101 Reykjavik, Iceland. E-mail: unnurav@hi.is

†Equal contributions.

Received 15 June 2021; Editorial decision 8 October 2021; Accepted 21 October 2021

Key Features

- COVIDMENT [www.covidment.is] is a NordForsk-funded research collaboration across six nations, with the overarching aim to significantly advance current knowledge on mental morbidity trajectories associated with the coronavirus disease 2019 (COVID-19) in the general population and in specific risk groups.
- From March 2020 through August 2021, 392 817 individuals have been recruited to the seven COVIDMENT cohorts: the Danish Blood Donor Study ($N = 71\,562$), the Estonian Biobank COVID-19 and Mental Health Data Collection cohorts ($N = 13\,329$ and $N = 86\,116$, respectively), the Icelandic COVID-19 National Resilience Cohort ($N = 22\,849$), the Norwegian BRY.DEG2020 ($N = 19\,343$), the Norwegian Mother, Father and Child Cohort Study ($N = 132\,486$), the Scottish Generation Scotland/CovidLife ($N = 18\,518$) and the Swedish Omtanke2020 ($N = 28\,614$). Semi-harmonized questionnaire data have been collected across all COVIDMENT cohorts with longitudinal data available, e.g. through linkage to the national registers.
- The average age of participants ranged from 31.8 to 58.5 years across cohorts. The prevalence of depressive symptoms above cut-off point varied considerably across cohorts (4.2–20.8%). The prevalence of depressive symptoms was highest at COVID-19 incidence of 30 cases per week per 100 000 persons, i.e. 14.3% [95% confidence interval (CI): 9.4–21.8%], which was 61.0% (95% CI: 34.0–94.1%) higher than the prevalence at COVID-19 incidence of 0 cases per week per 100 000 persons ($P = 1.1 \times 10^{-6}$).
- We welcome proposals for collaboration; please visit our website [www.covidment.is] for further information.

Why were the cohorts set up?

With more than 218 million cases and 4.5 million deaths worldwide (Worldometers, 31 August 2021), the COVID-19 pandemic has had an unprecedented influence on the global economy and population health. As a potent global disaster,

it is likely to significantly affect the incidence of adverse mental health symptoms and psychiatric disorders, particularly in vulnerable and highly affected populations. The World Health Organization and leading scientific journals have alerted concerning the potential adverse mental health impact

of COVID-19 and emphasized the need for multinational research in this area,^{1,2} which additionally provides new insights into disease mechanisms.²

Although a substantial number of studies on the mental health effects of COVID-19 has been published, the existing literature is largely limited by relatively small studies of convenience samples without pre-pandemic data, longitudinal data or cross-national comparisons.^{3,4} Some,^{5,6} but not all^{7,8} studies have reported evidence for a negative impact on mental health in the general adult population, including a rise in prevalence of symptoms of anxiety⁹ and depression^{10,11} during the COVID-19 pandemic. Previous history of psychiatric problems,¹² higher age¹³ and female sex¹⁴ have been suggested as risk factors for mental health problems during the COVID-19 pandemic, although the weight of these factors is bound to vary over time and geographical areas and largely depends on the severity of outbreaks. Furthermore, COVID-19-mandated restrictions, such as quarantine measures, complete or partial lockdown and isolation, have been associated with deterioration in mental health^{15–17} and so has dissatisfaction with governmental pandemic mitigations.¹⁸

The severity of the pandemic and mitigating strategies has varied considerably across countries. For example, as of 31 August 2021, the cumulative number of deaths due to COVID-19 stands at 1940 per one million inhabitants in the UK, 1440 in Sweden, 973 in Estonia, 444 in Denmark, 149 in Norway and 96 in Iceland (Worldometers, 2021). The variation in national pandemic response efforts and actual disease burden have implications for the proportion of citizens with first-hand exposure to COVID-19. Furthermore, mitigation responses may also affect health behaviours, social interactions, sense of security and trust in authorities, with potential downstream impact on population mental health. A key objective of the COVIDMENT initiative is to investigate whether differences in disease burden and mitigating responses to COVID-19 across countries (displayed in [Figure 1](#)) impact on psychiatric symptoms and disorders.

Due to the relatively narrow time window since the start of the pandemic, the long-term mental health consequences in exposed populations during the COVID-19 pandemic (i.e. patients, loved ones and front-line workers), as well as among those suffering unemployment or income losses, have not yet been sufficiently explored. Although research is still limited to small studies with short follow-up period, high prevalence of post-traumatic stress disorder (PTSD)^{19,20} and other mental health symptoms,²¹ along with elevated rates of diagnosed psychiatric disorders, have been observed during the first weeks after hospital discharge of COVID-19 inpatients.²² For how long

such adverse mental health effects remain after recovery from COVID-19 is yet to be investigated. Moreover, considerable mental health impact has been noted among family members of COVID-19 patients,³ with as yet unknown long-term consequences. Taken together, well-designed studies with long-term follow-up of COVID-19 patients, their loved ones and other high-risk groups are imperative for a comprehensive understanding of the mental health impact of the pandemic.¹

Based on the extensive research experience and existing infrastructures within the CoMorMent collaboration (an ongoing Horizon2020 programme on psychiatric and cardiometabolic comorbidities), we set out to establish new cohorts focusing on mental health indicators across six European nations during the pandemic. Funded by NordForsk (project No. 105668), the overarching aim of the COVIDMENT collaboration is to significantly advance current knowledge of long-term mental morbidity trajectories in the COVID-19 pandemic, both in the general population and in the specific risk groups.

Who is in the cohorts?

A total of 392 817 individuals have now been recruited to the cohorts and the timeline of each data collection is shown in [Figure 1](#). Background characteristics of all cohorts with currently available data for analysis ($N = 389\,925$) are shown in [Table 1](#) and the main sociodemographic characteristics of responders compared with the total population of each nation are shown in [Supplementary Table S1](#), available as [Supplementary data at IJE online](#). The design and recruitment process of each cohort are described below.

The Danish Blood Donor Study (DBDS)

DBDS is an ongoing national cohort study currently comprising about 120 000 blood donors²³ with about 95% participation rate among invited blood donors.²⁴ All participants answer a health-related questionnaire and provide a blood sample for research purposes. Prospective assessment of long-term health changes related to COVID-19 has been obtained thrice through the governmental, personal, password-protected e-mail-system e-boks.²⁵ The first wave of the COVID-19 questionnaire was sent out in May 2020 (participation rate 63.5%), the second was sent out in October 2020 (participation rate 63.7%) and the third was sent ultimo May 2021 and is still ongoing (medio August 2021). A total of 71 562 participants have answered at least one of the COVID-19 questionnaires, and among active DBDS blood donors, approximately 87 700 had been tested for SARS-CoV-2 antibodies by April 2021.




Figure 1 Daily COVID-19 cases per 100 000 persons, changes in social gathering restrictions (green means looser restrictions and red means stricter, according to Oxford COVID-19 Government Response Tracker) and timeline of waves (W) of data collections in each cohort

Participants lost to follow-up were slightly younger and less educated compared with those who remained in the cohort. Compared with the Danish national population above 18 years of age, the DBDS slightly over-sampled men, individuals of higher age (70+ years) and highly educated individuals. Written informed consents were collected from all participants. The study was funded by the Danish regions and the Independent Research Fund Denmark (0214-00127B).

The Estonian Biobank (EstBB) cohorts (EstBB-C19 and EstBB-MHDC)

EstBB is a population-based cohort ($N = 200\ 000$) with genotype and a rich variety of phenotypic and health-related information.²⁶ At recruitment, participants signed a broad consent form allowing follow-up linkage of their electronic health records (EHR) and contact for future studies, thereby providing a longitudinal collection of their phenotypic information. A COVID-19-related data

Table 1 Sociodemographic characteristics of the COVIDMENT cohorts

	Denmark (DBDS) (N = 68 973)	Estonia (EstBB-C19) (N = 13 329)	Estonia (EstBB-MHDC) (N = 86 116)	Iceland (C19-Resilience) (N = 22 849)	Norway (BRY.DEG2020) (N = 19 343)	Norway (MoBa) ^b (N = 132 486)	Scotland/UK (GS/CovidLife) (N = 18 518)	Sweden (Omtanke2020) (N = 28 311)
Gender								
Male	34 999 (50.7%)	4061 (30.5%)	25 278 (29.4%)	6872 (30.1%)	4640 (24.0%)	56 934 (42.3%)	6014 (32.5%)	5234 (18.5%)
Female	33 974 (49.3%)	9268 (69.5%)	60 838 (70.7%)	15 933 (69.7%)	14 584 (75.4%)	75 552 (57.7%)	12 375 (66.8%)	23 077 (81.5%)
Other	–	–	–	44 (0.2%)	119 (0.6%)	–	–	0 (0.0%)
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	129 (0.7%)	0 (0.0%)
Age (years)								
Mean age (SD)	58.5 (17.0)	44.1 (13.4)	48.4 (14.6)	54.4 (14.3)	31.8 (12.8)	46.7 (5.5)	56.4 (14.3)	48.6 (15.8)
18–29	5547 (8.0%)	1778 (13.3%)	8897 (10.3%)	1472 (6.4%)	11 716 (60.6%)	–	986 (5.3%)	3940 (13.9%)
30–39	6878 (10.0%)	3779 (28.4%)	17 863 (20.7%)	2238 (9.8%)	2861 (14.8%)	11 193 (8.5%)	1798 (9.7%)	5218 (18.4%)
40–49	9265 (13.4%)	3329 (25.0%)	19 412 (22.5%)	4043 (17.7%)	2315 (12.0%)	83 164 (62.8%)	2567 (13.9%)	5411 (19.1%)
50–59	11 303 (16.4%)	2518 (18.9%)	18 968 (22.0%)	5871 (25.7%)	1609 (8.3%)	36 195 (27.3%)	4055 (21.9%)	6043 (21.4%)
60–69	8656 (12.5%)	1379 (10.4%)	13 505 (15.7%)	5890 (25.8%)	656 (3.4%)	1801 (1.4%)	5526 (29.8%)	4462 (15.8%)
70+	27 324 (39.6%)	546 (4.1%)	7471 (8.7%)	3334 (14.6%)	186 (1.0%)	98 (0.0%)	3376 (18.2%)	3237 (11.4%)
Missing	–	–	–	–	–	35 (0.0%)	210 (1.1%)	–
Education								
Compulsory	3956 (5.7%)	277 (2.1%)	3057 (3.6%)	3305 (14.5%)	91 (0.5%)	3536 (2.7%)	1538 (8.3%)	^d
Upper secondary, Vocational, or other ^c	2252 (3.3%)*	5101 (38.3%)	34 475 (40.0%)	7080 (31.0%)	3194 (16.5%)	43 137 (32.6%)	6153 (33.2%)	
Bachelor's/diploma university degree	47 056 (68.2%)	3638 (27.3%)	20 816 (24.2%)	7161 (31.3%)	7468 (38.6%)	43 426 (32.8%)	4204 (22.7%)	
Master's or PhD	14 502 (21.0%)	4155 (31.2%)	27 125 (31.5%)	5148 (22.5%)	3739 (19.3%)	29 358 (22.2%)	4526 (24.4%)	
No formal education	818 (1.2%)	–	185 (0.2%)	–	–	–	385 (2.1%)	
Missing	389 (0.6%)	158 (1.2%)	458 (0.5%)	155 (0.7%)	4510 (25.1%)	13 029 (9.8%)	1712 (9.2%)	
Marital status								
In a relationship	41 721 (60.5%)	–	62 546 (72.6%)	17 455 (76.4%)	8690 (43.3%)	–	13 962 (75.4%)	20 500 (72.4%)
Single	26 554 (38.5%)		22 960 (26.7%)	5292 (23.2%)	10 974 (56.7%)		4185 (22.6%)	7664 (27.1%)
Missing	698 (1.0%)		610 (0.7%)	102 (0.4%)	0 (0.0%)		371 (2.0%)	147 (0.5%)
Body mass index (BMI, kg/m ²)								
<25, normal weight	30 681 (44.4%)	5840 (43.8%)	38 147 (44.3%)	6601 (28.9%)	–	34 910 (43.5%)	7190 (38.8%)	14 467 (51.1%)
25–30, overweight	26 599 (38.6%)	4002 (30.0%)	27 586 (32.0%)	8797 (38.5%)		30 300 (37.7%)	6296 (34.0%)	8169 (28.9%)
>30, obese	10 985 (15.9%)	2531 (19.0%)	18 139 (21.1%)	6881 (30.1%)		13 876 (17.3%)	4644 (25.1%)	3707 (13.1%)
Missing	708 (1.0%)	956 (7.2%)	2244 (2.6%)	570 (2.5%)		1188 (1.5%)	388 (2.1%)	1968 (6.9%)

(Continued)

Table 1 Continued

	Denmark (DBDS) (N = 68 973)	Estonia (EstBB-C19) (N = 13 329)	Estonia (EstBB-MHDC) (N = 86 116)	Iceland (C19-Resilience) (N = 22 849)	Norway (BRY.DEG2020) (N = 19 343)	Norway (MoBa) ^b (N = 132 486)	Scotland/UK (GS/CovidLife) (N = 18 518)	Sweden (Omtanke2020) (N = 28 311)
Current smoking								
No	62 345 (90.4%)	10 944 (82.1%)	63 877 (74.2%)	19 900 (87.1%)	15 643 (80.9%)	84 523 (63.8%)	16 413 (88.6%)	22 824 (80.6%)
Yes	6549 (9.5%)	1787 (13.4%)	19 049 (22.1%)	2808 (12.3%)	3700 (19.1%)	8383 (6.3%)	1317 (7.1%)	4662 (16.5%)
Missing	79 (0.1%)	598 (4.5%)		141 (0.6%)	–	39 580 (29.9%)	788 (4.3%)	825 (2.9%)
Somatic diseases ^a								
None	15 452 (22.4%)	7469 (56.0%)	^d	13 359 (58.5%)	–	94 375 (71.2%)	11 231 (60.6%)	18 726 (66.1%)
One	15 786 (22.9%)	3914 (29.4%)		6577 (28.8%)		17 671 (13.3%)	5076 (27.4%)	6500 (23.0%)
Two	10 046 (14.6%)	1004 (7.5%)		2112 (9.2%)		2141 (1.6%)	1501 (8.1%)	1731 (6.1%)
>Two	7716 (11.2%)	410 (3.1%)		650 (2.8%)		302 (0.2%)	425 (2.3%)	604 (2.1%)
Missing	19 973 (29.0%)	532 (4.0%)		151 (0.7%)		17 997 (13.6%)	285 (1.5%)	750 (2.6%)
COVID-19 diagnosis								
No	49 460 (71.7%)	9863 (74.0%)	^d	21 916 (95.9%)	16 625 (86.0%)	130 889 (98.8%)	15 109 (88.9%)	11 887 (42.0%)
Yes	3000 (4.3%)	3356 (25.2%)		933 (4.1%)	2671 (13.8%)	1597 (1.2%)	1706 (10.1%)	2387 (8.4%)
Missing	16 513 (24.0%)	110 (0.8%)		0 (0.0%)	47 (2.4%)	0 (0.0%)	182 (1.1%)	14 037 (49.6%) ^c

Missing means not tested in Sweden.

SD, standard deviation.

^aSomatic diseases include hypertension, heart disease, lung disease, chronic renal failure, cancer, diabetes or immune suppression/immunosuppressive therapy.

^bAmount of missing in MoBa data also reflects MoBa Corona data collections with varying response rate.

^cVocational school was in the same category as Bachelor's/diploma university degree for Danish cohort.

^dWill be obtained from registers.

collection (EstBB-C19) was established in May 2020 when invitations to fill in web-based questionnaires, including questions on COVID-19 symptoms and associated risk factors as well as mental health assessments, were sent out to EstBB participants who had been tested for SARS-CoV-2 with a reverse transcription polymerase chain reaction (RT-PCR) test, based on EHR updates. Personal invitations were sent out between May and December 2020, and thereafter the questionnaire was available to the full EstBB cohort upon login to the online participant survey environment. Currently, 13 329 individuals have responded (participation rate 12.4%). A more comprehensive mental health questionnaire-based data collection (EstBB-MHDC, $N = 86\,116$ responders) was carried out in the full EstBB cohort from March to July 2021 and is currently in preparation for analysis (participation rate 46.7%). A total of 184 622 invitations were sent out by e-mail to all living EstBB participants with a valid e-mail address and the recruitment was accompanied by a media campaign to increase participation rate. The EstBB C19 and MHDC cohorts over-represent women, individuals between 30 and 59 years of age and those with higher education, when compared with the general population of Estonia. The research in the Estonian Biobank was supported by the European Union through the European Regional Development Fund (project no. 2014-2020.4.01.15-0012), and the Estonian Research Council through grant no. PSG615, the programme Mobilias Plus (MOBTP142), funding of Estonian sub-project of NordForsk project no. 105668, and National Programme for Addressing Socio-Economic Challenges through R&D (RITA), supported by the Estonian Government and European Regional Development Fund (RITA1/02-112).

The Icelandic COVID-19 national resilience cohort (C-19 Resilience)

C-19 Resilience was established in April 2020, with the overarching aim of understanding the long-term public health impact of the COVID-19 pandemic in Iceland. Eligible for participation were all Icelandic and English-speaking individuals 18 years or older who had an Icelandic electronic ID (as of 1 January 2020, the total adult population was 282 770). Recruitment was obtained via social media and invitations were sent to participants in ongoing cohort studies in Iceland [the SAGA cohort ($N = 31\,795$ women), iStopMM ($N = 80\,730$ men and women) and Health and Well-being of Icelanders ($N = 6102$ men and women)]. In addition, all individuals in Iceland who tested positive for SARS-CoV-2 by RT-PCR in Iceland through 2020 received an invitation in June 2020 and February 2021 ($N = 4262$; response rate 21.8%). All participants signed an electronic informed

consent and subsequently answered a web-based questionnaire. To August 2021, two waves of follow-ups have been completed with 24 917 providing informed consent (8.8% of the total population); 22 849 of these participants have complete data, of whom 15 832 (63.5%) have provided data at more than one time point). Participants lost to follow-up are slightly younger (mean age 52.3 years vs 55.1 years) but only minor differences were found for sex and education. The C-19 Resilience cohort is over-represented by women and participants are on average of higher age and education compared with the general population. The study was originally supported with funds from the Icelandic government.

The Norwegian BRY.DEG2020

BRY.DEG2020 (TAKE.CARE2020) is a longitudinal survey study established in March 2020 at the University of Bergen and Haukeland University Hospital, with the overarching aim to monitor the effect of the pandemic and its restrictions on mental health, using self-report data. Participants were recruited via social media and e-mail lists for universities across Norway and from patient organizations. Participants aged 18 years and older signed an informed consent before answering the survey. The first study wave was sent out in April 2020 ($N = 19\,343$, of whom 13 500 agreed to be recontacted), the second in December 2020 ($N = 6320$) and the third is planned in October 2022.²⁷ Compared with the general Norwegian population, women and young individuals with higher education are over-represented in BRY.DEG2020. The group lost to follow-up differed from those remaining by having a lower age (mean age 30.6 vs 34.7 years), more men, more students and fewer with a completed bachelor's degree. The project was funded by the University of Bergen and Helse Bergen.

The Norwegian Mother, Father and Child Cohort study (MoBa)

MoBa is a population-based pregnancy cohort study conducted by the Norwegian Institute of Public Health.²⁸ Pregnant women attending a routine ultrasound examination were invited and recruited from all over Norway in 1999–2008. The participation rate is 41%. During the pregnancy and with regular follow-up questionnaires, participants (mothers, fathers and children) have completed extensive questionnaires on lifestyle, health and well-being. The cohort now includes 114 500 children (aged 12–22 years), 95 200 mothers and 75 200 fathers. Since March 2020, all adult MoBa participants have been invited to complete short bi-weekly COVID-19 surveys,

with some repeated questions. As of August 2021, 35 waves of data collection have been completed, including responses from more than 132 486 adults (participation rate ranging from 46% to 83%). Like in other pregnancy cohorts, MoBa participants have healthier lifestyle and higher socioeconomic position than the general population. Younger women, smokers and women with low educational level were less likely to participate.²⁹ MoBa is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. MoBa researchers and the COVID-19 data collection in MoBa are supported by the Research Council of Norway (223 273, 273 291, 312 721, 324 620).

The Scottish Generation Scotland study

The Scottish Generation Scotland study (GS)³⁰ is a population- and family-based cohort with broad consent for genetic, health, well-being and lifestyle studies. The main recruitment (24 096 individuals in 5501 family groups) took place during 2006–11. In 2020, a series of CovidLife surveys³¹ were conducted to measure mental health during the COVID-19 pandemic. Survey invitations were sent to 22 796 members of GS who provided an e-mail address for recontact, as well as to other adults in the UK through collaborators and social media channels. The first wave ran from April 2020 [$N = 18\,518$, of whom 16 995 resided in Scotland, 1395 elsewhere in the UK and 4847 were GS participants (21.3% of those invited)], the second from July 2020 ($N = 11\,319$) and the third from February 2021 ($N = 10\,386$). Women, participants aged over 50 and those with higher qualifications were over-represented in the CovidLife sample compared with the Scottish population. Except for age, demographics (e.g. sex and education) remained largely consistent with those reported at baseline, suggesting minimal effects of attrition. The mean age was higher in follow-ups (FU) (FU1 = 58.6 years, FU2 = 59.0 years) than at baseline (56.4 years). GS received support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006) and is currently supported by the Wellcome Trust (216767/Z/19/Z). Recruitment to the CovidLife study was facilitated by SHARE, the Scottish Health Research Register and Biobank. SHARE is supported by NHS Research Scotland, the Universities of Scotland and the Chief Scientist Office of the Scottish Government.

The Swedish Omtanke2020

With funding from Swedish Research Council (grant number D0886501), Omtanke2020 started in June 2020 and is an

ongoing prospective, longitudinal cohort study with monthly data collections from volunteering participants through online surveys. It is open to participation to all residents of Sweden who are 18 years or older, and have the electronic identification BankID. Participants are recruited through mass media or invitations sent to participants of existing cohorts [mainly LifeGene ($N = 3592$), KARMA ($N = 5342$, all women), Swedish Twin Registry ($N = 3460$); participation rate is 7–11%, depending on the cohort]. Recruitment ended on 8 June 2021. To August 2021, up to 12 waves (baseline and 11 follow-ups) have been completed [baseline ($N = 28\,293$ completed/28 614 started), FU1 ($N = 20\,543$), FU2 ($N = 17\,743$), FU3 ($N = 14\,619$), FU4 ($N = 12\,790$), FU5 ($N = 11\,506$), FU6 ($N = 10\,629$, long follow-up), FU7 ($N = 9496$), FU8 ($N = 7107$), FU9 ($N = 4757$), FU10 ($N = 3303$) and FU11 ($N = 2208$, last monthly follow-up)]. Waves 2–12 are still open, but currently participants aged 50 years or younger and men are slightly more likely to drop out. Mean age for those who dropped out after baseline is 45.3 years and the mean age for those who filled out at least one follow-up survey is 49.5 years. Compared with the general population of Sweden, women, persons aged between 40 and 69 years and urban residents are over-represented in the cohort. Further information will be obtained through annual follow-ups (starting Winter 2021/22) and linkage to Swedish population and health registers as well as the existing cohorts.

What has been measured?

Questionnaires in all cohorts include several validated mental health instruments, including screening measures for depressive symptoms [measured with Patient Health Questionnaire-9 (PHQ-9),³² Emotional State Questionnaire (EST-Q2)],^{33,34} anxiety [General Anxiety Disorder-7 (GAD-7),³⁵ EST-Q2,³⁴ the Dimensional Obsessive-Compulsive Scale (DOCS-SF)],³⁶ PTSD [the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5),³⁷ PTSD Checklist for DSM-5 (PCL) short form],³⁸ stress [Perceived Stress Scale 4 (PSS-4),³⁹ Perceived Stress Scale 10 (PSS-10),⁴⁰ Impact of Event Scale—Revised (IES-R-15)],⁴¹ loneliness [UCLA Loneliness Scale version 3 (UCLA-3),⁴² EST-Q2]³⁴ sleep [Pittsburgh Sleep Quality Index (PSQI),⁴³ EST-Q2,³⁴ Bergen Insomnia Scale (BIS)],⁴⁴ fatigue [EST-Q2,³⁴ Chalder Fatigue Questionnaire (CFQ)],⁴⁵ cognitive function [Patient-Reported Outcomes Measurement Information System (PROMIS) short form]⁴⁶ as well as happiness (summarized in [Table 2](#)). In addition, participants in each cohort answered extensive questionnaires on general health and working and life conditions during COVID-19, as well as questions on COVID-19-specific factors, such as COVID-19 symptoms, SARS-CoV-2 infection status and hospitalization (see [Supplementary Table S2](#), available as

Table 2 Validated mental health instruments in the COVIDMENT cohorts, including register data

	Denmark DBDS	Estonia EstBB-C19	Estonia EstBB-MHDC	Iceland C19-Resilience	Norway BRY.DEG2020	Norway MoBa	Scotland/UK GS/CovidLife	Sweden Omtanke2020
Depression	PHQ-9	EST-Q2	EST-Q2	PHQ-9	PHQ-9	PHQ-9	PHQ-9	PHQ-9
Anxiety	ASS	EST-Q2	EST-Q2	GAD-7	GAD-7; DOCS-SF	GAD-7	GAD-7	GAD-7
PTSD	PC-PTSD-5		PCL short form	PC-PTSD-5 (modified)		PC-PTSD-5		PC-PTSD-5 (modified)
Stress	PSS-10		Single item	PSS-4	IES-R-15	PSS-4	PSS-4; Stressed by C19	PSS-4
Mental health (general)	SF-12		Single item	SRMH		HSCL-5	SWEMWBS	SRMH
Pre-existing psychiatric conditions	*	*	x/*	x/*	x	x	x	x
Happiness	Single item		Single item	Single item		SWLS		Single item
Loneliness	UCLA-3	Single item from EST-Q2	Single item from EST-Q2	Single item from UCLA	UCLA-3		Single item	Single item
Sleep	Sleep quality; insomnia; daytime fa- tigue; restless legs; average hours	EST-Q2	EST-Q2	5 items from the PSQI	BIS	PSQI	Average hours, sleep quality	5 items from PSQI
Fatigue	Daytime fatigue (3 items)	EST-Q2	EST-Q2	Single item	Single item	CFQ; long Covid items		Single item (since July 2021)
Cognitive function			Four items	PROMIS short form		Difficulty concentrating; harder to find the right word; memory	Digit-symbol, verbal fluency, vocabulary, logical memory	Difficulty concentrating (since July 2021)

Data from surveys are marked with x; register data are marked with *.

PHQ-9, Patient Health Questionnaire;²⁹ EST-Q2, Emotional State Questionnaire;³⁰ GAD-7, General Anxiety Disorder;³¹ ASS, Angst-Symptom-Spørgeskemaet;⁴⁴ DOCS-SF, Dimensional Obsessive-Compulsive Scale;³² PC-PTSD-5, Primary Care PTSD Screen for DSM-5;³³ PCL, PTSD Checklist;³⁴ PSS-4³⁵/PSS-10,³⁶ Perceived Stress Scale; IES-R-15, Impact of Event Scale—Revised;³⁷ SRMH, Self-rated Mental Health;⁴⁵ SF-12, Short-Form Health Survey;⁴⁶ HSCL-5⁴⁷, Hopkins Symptom Checklist; SWEMWBS, Short Warwick-Edinburgh Mental Well-being Scale;⁴⁸ SWLS, Satisfaction With Life Scale;⁴⁹ UCLA-3, Loneliness Scale Version 3;⁵⁰ PSQI-9, Pittsburgh Sleep Quality Index³⁹ BIS, Bergen Insomnia Scale;⁴⁰ CFQ, Chalder Fatigue Scale;⁴¹ PROMIS, Patient-Reported-Outcomes-Measurement Information System.⁴²

[Supplementary data at IJE online](#), for a detailed overview of measures).

Pre-COVID mental health data are available for participants of all cohorts through self-reports or record linkage to population registers. Most cohorts are linked to national health registries, with lifelong data on mental disorders and comorbid diseases including pre-COVID conditions and long-term post-COVID outcomes. Several cohorts also include biobanks that will be used to study genetic and biological risk factors.

What has it found? Key findings

Table 1 shows the sociodemographic characteristics of the COVIDMENT cohorts. Most of the cohorts had higher levels of female participation (57.7–81.5%), except the Danish DBDS with 50.7% males. The mean age of cohort participants ranged from 44.1 years (Estonian EstBB-C19) to 58.5 years (Danish DBDS) and the majority were in a relationship (60.5–76.4%). An exception is the Norwegian BRY.DEG2020 where the mean age was 31.8 years and 56.7% of participants were single. The highest educational level varied between cohorts, e.g. university education or higher was reported by 89.2% in the Danish DBDS and 47.1% in the Scottish CovidLife.

In terms of health-related risk factors, the highest prevalence of obesity was observed in the Icelandic C-19 Resilience (30.1%) and the lowest prevalence was observed in the Swedish Omtanke2020 (13.3%). The highest prevalence of current smoking was in the Norwegian BRY.DEG2020 (19.1%) and the lowest in the Norwegian MoBa (6.3%). The proportion with chronic somatic diseases (e.g. hypertension, lung disease) varied considerably across cohorts, ranging from 15.1% in the Norwegian MoBa to 48.7% in the Danish DBDS. The highest proportion of participants infected with SARS-CoV-2 was in the Estonian EstBB-C19 (25.2%) and the Norwegian BRY.DEG2020 (13.8%). The corresponding proportion was 10.1% in the Scottish CovidLife, 8.4% in the Swedish Omtanke2020, 4.3% in the Danish DBDS, 4.1% in the Icelandic C-19 Resilience and 1.2% in the Norwegian MoBa.

Table 3 shows the prevalence of depressive symptoms above cut-off (measured as ≥ 10 on PHQ-9/ > 11 on EST-Q2) across cohorts adjusted for or stratified by age and sex. The overall prevalence of reporting depressive symptoms above cut-off ranged from 4.2% to 20.8% across the cohorts, namely 20.8% in Scottish CovidLife, 17.1% in Norwegian BRY.DEG2020, 17.1% in Swedish Omtanke2020, 16.6% in Icelandic C-19 Resilience, 15.0% in Estonian EstBB-C19, 7.6% in Danish DBDS and 4.2% in Norwegian MoBa. Across all cohorts, the average prevalence of depressive symptoms was 12.7% (95% CI: 8.0–19.8%) after adjusting

for age, sex and season. The highest prevalence of depressive symptoms was consistently noted among young adults, i.e. 18–29 years of age, declining sharply thereafter in a stepwise fashion. Similarly, the prevalence of depressive symptoms was higher among females (5.0–24.4%) than males (3.5–17.7%) after adjusting for age.

Figure 2 shows the prevalence of depressive symptoms above cut-off for all cohorts (excluding COVID-19 cases) by nationwide incidence of weekly COVID-19 cases per 100 000 persons during the 2 preceding weeks before responding to the PHQ-9/EST-Q2. We used a generalized additive mixed model to fit a multi-level model to the data, with a random effect for each study to account for correlations in the data within each study. The association between the prevalence of depressive symptoms with COVID-19 incidence was modelled using penalized regression spline for week (**Supplementary Figure S1**, available as [Supplementary data at IJE online](#)). The distribution of the outcome was assumed quasi-binomial and each observation was weighted with the accompanying sample size. The adjustment for season was made by using a penalized spline for week (**Supplementary Figure S2**, available as [Supplementary data at IJE online](#)). Trends varied across countries (**Supplementary Table S3**, available as [Supplementary data at IJE online](#)) but overall we found the association to be non-linear. The prevalence of depressive symptoms was highest at 14.3% (95% CI: 9.4–21.8%) when the COVID-19 incidence was around 30 weekly cases per 100 000 persons. This represents 61.0% (95% CI: 34.0–94.1%) higher prevalence of depressive symptoms than the prevalence, 8.9% (95% CI: 5.6–13.6%), at a COVID-19 incidence of 0 weekly cases per 100 000 persons. When the COVID-19 incidence was 60 weekly cases per 100 000 persons, the prevalence of depressive symptoms was 12.4% (95% CI: 7.9–19.4%), close to the average prevalence (**Supplementary Figure S3**, available as [Supplementary data at IJE online](#)). Combined, these results suggest some influence of weekly COVID-19 incidence on population depressive symptoms primarily at the lower range of incidence rates, possibly reflecting early rise or the end of an epidemic wave.

What are the main strengths and weaknesses?

The COVIDMENT project is a large-scale multinational collaboration between Denmark, Estonia, Iceland, Norway, Scotland and Sweden, which was established to significantly advance current knowledge of mental morbidity trajectories during and beyond the COVID-19 pandemic, by using ongoing semi-harmonized batteries of validated mental health assessments with longitudinal follow-up of 392 817 individuals, as well as large, data-rich record linkages to the national

Table 3 Proportion above cut-off for depressive symptoms across categories of gender and age in the COVIDMENT cohorts

	Denmark DBDS (N = 68 973)		Estonia EstBB-C19 (N = 11 289)		Iceland C19-Resilience (N = 22 849)		Norway BRY.DEG2020 (N = 19 343)		Norway MoBa (N = 91 950)		Scotland/UK CovidLife (N = 16 356)		Sweden Omtanke2020 (N = 27 952)	
	N ≥10 PHQ-9	% (95% CI)	N >11 EST-Q2	% (95% CI)	N ≥10 PHQ-9	% (95% CI)	N ≥10 PHQ-9	% (95% CI)	N ≥10 PHQ-9	% (95% CI)	N ≥10 PHQ-9	% (95% CI)	N ≥10 PHQ-9	% (95% CI)
Total	5946	7.6% (7.4–7.9%) ^a	2335	15.0% (14.2–15.8%) ^a	4084	16.6% (16.0–17.2%) ^a	7059	17.1% (16.1–18.1%) ^a	4482	4.2% (4.0–4.3%) ^a	3268	20.8% (20.0–21.6%) ^a	4946	17.1% (16.5–17.7%) ^a
Gender														
Male	2189	6.1% (5.9–6.4%) ^b	476	11.9% (10.9–13.0%) ^b	778	13.5% (12.7–14.4%) ^b	1411	15.1% (14.2–16.2%) ^b	1364	3.5% (3.3–3.7%) ^b	732	17.7% (16.6–18.9%) ^b	720	14.8% (14.0–15.7%) ^b
Female	3757	9.5% (9.2–9.8%) ^b	1859	18.8% (17.8–19.8%) ^b	3287	20.2% (19.6–20.8%) ^b	5587	19.2% (18.2–20.3%) ^b	3118	5.0% (4.8–5.2%) ^b	2536	24.4% (23.6–25.2%) ^b	4226	19.8% (19.2–20.3%) ^b
Other	–	–	–	–	19	35.8% (26.0–49.3%) ^b	61	24.4% (20.5–29.0%) ^b	–	–	–	–	–	–
Missing	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Age (years)														
18–29	1292	21.1% (21.1–22.2%) ^c	506	30.7% (28.4–33.1%) ^c	630	37.0% (34.7–39.5%) ^c	5332	42.5% (41.5–43.6%) ^c	–	–	366	45.0% (41.6–48.6%) ^c	1322	38.5% (36.88–40.1%) ^c
30–39	919	12.7% (12.0–13.5%) ^c	758	21.5% (20.1–23.0%) ^c	702	27.0% (25.2–28.9%) ^c	895	29.2% (27.6–30.9%) ^c	541	7.8% (7.2–8.5%) ^c	535	31.5% (29.2–33.9%) ^c	1190	26.2% (24.9–27.5%) ^c
40–49	840	8.7% (8.2–9.3%) ^c	552	17.6% (16.3–19.0%) ^c	877	19.2% (18.0–20.4%) ^c	457	18.2% (16.7–19.8%) ^c	2729	4.4% (4.3–4.6%) ^c	644	25.5% (23.8–27.4%) ^c	886	19.0% (17.9–20.1%) ^c
50–59	765	6.6% (6.1–7.0%) ^c	331	13.3% (12.0–14.8%) ^c	928	14.3% (13.4–15.2%) ^c	277	16.0% (14.3–17.8%) ^c	1159	4.2% (4.0–4.5%) ^c	794	20.2% (18.9–21.6%) ^c	830	14.9% (14.0–15.9%) ^c
60–69	393	4.5% (4.1–4.9%) ^c	143	10.7% (9.2–12.5%) ^c	714	11.2% (10.5–12.0%) ^c	79	11.4% (9.3–14.0%) ^c	53	4.4% (3.4–5.7%) ^c	669	12.7% (11.8–13.6%) ^c	437	10.0% (9.2–10.9%) ^c
70+	1737	6.4% (6.2–6.7%) ^c	45	8.8% (6.7–11.7%) ^c	233	6.7% (5.9–7.6%) ^c	19	10.2% (6.4–15.0%) ^c	–	–	260	8.1% (7.3–9.1%) ^c	281	8.0% (7.2–9.0%) ^c

Data until 12 August 2021 for all cohorts. Total number of participants is less than in Table 1 due to missing responses or ongoing inclusion in all cohorts.

^aAdjusted to age 50 years and gender distribution (males 49.9%, females 49.9%, other 0.2%).

^bAdjusted to age 50 years.

^cAdjusted for gender distribution (males 49.9%, females 49.9%, other 0.2%).




Figure 2 National COVID-19 incidence and depressive symptoms across cohorts. The COVID-19 incidence is defined as the average number of confirmed cases per week per 100 000 persons in the 2 weeks prior to participants' response to the PHQ-9/EST-Q2 (COVID-19 cases excluded). Dotted black line represents trend with 95% confidence interval (blue area)

health registry resources. These resources are well powered for a systematic exploration of trans-national heterogeneity in pandemic effects, including how variations in mitigating responses to COVID-19 pandemic and disease burden across countries impact on psychiatric symptoms and disorders, both in exposed populations and on a population level.

A weakness of the COVIDMENT project is that different strategies were used for recruitment to the various cohorts. Some cohorts, for example MoBa, EstBB-C19 and DBDS, consist of already established cohorts, some perhaps with over-representation of healthy individuals (e.g. blood donors and parents). Other cohorts, such as Omtanke2020, BRY.DEG2020 and C-19 Resilience, sent invitations to existing cohort members but also opened for volunteering participants through social media, which may have resulted in selection bias. Indeed, compared with the general populations, most of the cohorts include an over-representation of women as well as individuals of older age and higher education.^{48–59} Recruitment differences may to some extent explain the differences in prevalence of depressive symptoms above cut-off across cohorts. Yet, prevalence differences in depressive disorders have been observed across European countries using similar recruitment.⁴⁷ Also, some cohorts targeted invitations to individuals diagnosed with SARS-CoV-2 or tested for SARS-CoV-2 with an RT-PCR test (i.e. C-19 Resilience and EstBB-C19), whereas other cohorts did not. The different recruitment strategies across cohorts may to some extent explain the higher levels of depressive symptoms

when tested individuals are targeted for inclusion. Second, the cohorts rely on self-reported questionnaire data with associated risks of measurement errors. However, this risk is mitigated by also obtaining data on clinical diagnoses of psychiatric disorders from the population registers, which is a distinctive feature of the participating cohorts and countries.

Can I get hold of the data? Where can I find out more?

The individual-level data underlying this article were subject to ethical approval and cannot be shared publicly due to data protection laws in each participating country. The data can be shared on reasonable request to the corresponding author. We encourage scientists who are interested in collaboration with the COVIDMENT project to contact investigators via the study website [www.covidment.is] or reach out to the principal investigator of the project. Prof. Valdimarsdóttir [unnurav@hi.is], for further information.

Ethics approval

The DBDS was approved by the Zealand and Central Denmark Regional Committees on Health Research Ethics (SJ-740 and M-2009237) and the Data Protection Agency (P-2019–99). The EstBB-C19 and EstBB-MHDC were approved by the Estonian Committee on Bioethics and Human Research (1.1–12/1277 and 1.1–12/2860). The C-19 Resilience was approved by the National

Bioethics Committee (NBC no. 20–073, 21–071) as well as the National Data Protection Authority. The BRY.DEG2020 was approved by the Regional Committees for Medical and Health Research Ethics (123324). The MoBa was approved by the Regional Committees for Medical and Health Research Ethics (127708/14140/20138); this also includes approval to link the MoBa data with data from national health registries (including psychiatric and COVID-19 diagnostic information). The GS was approved by the East of Scotland Research Ethics Service (EoSRES). The Omtanke2020 ethical approval no. is 2020–01785.

Supplementary Data

Supplementary data are available at *IJE* online.

Funding

This work was partly supported by NordForsk through the funding to mental morbidity trajectories in COVID-19 across risk populations of five nations, project number 105668. T.F.H. is supported by the Novo Nordisk Foundation (grants NNF14CC0001, NNF17OC0027594) and Candy's Foundation. L.Y. is supported by US NIMH (R01 MH123724).

Author Contributions

The COVIDMENT cohorts and/or their data collections were designed by A.B.U., A.L., C.F-R., H.A., K.K., K.H., M.D., D.J.P., F.F., K.L., R.M., L.M., O.A.A., O.B.V.P., S.L.H., U.A.V. and their respective teams. U.A.V. and A.B.U. directed the combined effort of this study implementation. U.A.V. and T.A. designed the analytical strategy in close collaboration with all team members, and all authors helped to interpret the findings. A.B.U., A.L., C.F-R., H.A., K.K., K.H., M.D. and L.A.N.C. conducted the literature review and drafted the manuscript under supervision of U.A.V. All authors revised the manuscript for critical content and approved the final version of the manuscript.

Conflict of Interest

A.M. has received speakers' fees from Illumina and Janssen and has received research grant funding from the Sackler Trust, outside of the current work. All other authors declare no conflict of interest.

References

1. Editorial. Keep mental health in mind. *Nat Med* 2020;26:631.
2. Holmes EA, O'Connor RC, Perry VH *et al*. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry* 2020;7:547–60.
3. Rogers JP, Chesney E, Oliver D *et al*. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020;7:611–27.
4. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. *Brain Behav Immun* 2020;89:531–42.
5. Daly M, Sutin AR, Robinson E. Longitudinal changes in mental health and the COVID-19 pandemic: evidence from the UK Household Longitudinal Study. *Psychol Med* 2020;Nov 13:1–10.
6. Pierce M, Hope H, Ford T *et al*. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. *Lancet Psychiatry* 2020;7:883–92.
7. Knudsen AKS, Stene-Larsen K, Gustavson K *et al*. Prevalence of mental disorders, suicidal ideation and suicides in the general population before and during the COVID-19 pandemic in Norway: a population-based repeated cross-sectional analysis. *Lancet Reg Health Eur* 2021;4:100071.
8. van der Velden PG, Hyland P, Contino C, von Gaudecker HM, Muffels R, Das M. Anxiety and depression symptoms, the recovery from symptoms, and loneliness before and after the COVID-19 outbreak among the general population: findings from a Dutch population-based longitudinal study. *PLoS One* 2021;16:e0245057.
9. Kwong ASF, Pearson RM, Adams MJ *et al*. Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts. *Br J Psychiatry* 2020;Nov 24:1–10.
10. Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: a meta-analysis of community-based studies. *Int J Clin Health Psychol* 2021;21:100196.
11. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. *JAMA Netw Open* 2020;3:e2019686.
12. Hao F, Tan W, Jiang L *et al*. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. *Brain Behav Immun* 2020;87:100–06.
13. Grolli RE, Mingoti MED, Bertollo AG *et al*. Impact of COVID-19 in the mental health in elderly: psychological and biological updates. *Mol Neurobiol* 2021;58:1905–12.
14. Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – a systematic review and meta-analysis. *Psychiatry Res* 2020;291:113190.
15. Creese B, Khan Z, Henley W *et al*. Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. *Int Psychogeriatr* 2020;33:1–10.
16. Tang F, Liang J, Zhang H, Kelifa MM, He Q, Wang P. COVID-19 related depression and anxiety among quarantined respondents. *Psychol Health* 2021;36:164–78.
17. Wu T, Jia X, Shi H *et al*. Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. *J Affect Disord* 2021;281:91–98.
18. Mækela M, Reggev N, Dutra N *et al*. Perceived efficacy of COVID-19 restrictions, reactions and their impact on mental health during the early phase of the outbreak in six countries. *R Soc Open Sci* 2020;7:200644.
19. Bo HX, Li W, Yang Y *et al*. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically

- stable patients with COVID-19 in China. *Psychol Med* 2021;51:1052–53.
20. Zhang J, Lu H, Zeng H *et al.* The differential psychological distress of populations affected by the COVID-19 pandemic. *Brain Behav Immun* 2020;87:49–50.
 21. Mazza MG, De Lorenzo R, Conte C *et al.*; COVID-19 BioB Outpatient Clinic Study group. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. *Brain Behav Immun* 2020;89:594–600.
 22. Taquet M, Luciano S, Geddes J, Harrison P. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *Lancet Psychiatry* 2021;8:130–40.
 23. Pedersen O, Erikstrup C, Kotze SR *et al.* The Danish Blood Donor Study: a large, prospective cohort and biobank for medical research. *Vox Sang* 2012;102:271.
 24. Burgdorf K, Felsted N, Mikkelsen S *et al.* Digital questionnaire platform in the Danish blood donor study. *Comput Methods Programs Biomed* 2016;135:101–04.
 25. Didriksen M, Werge T, Nissen J *et al.* Impact of COVID-19 Pandemic on sleep quality, stress level and health-related quality of life—a large prospective cohort study on adult Danes. *Int J Environ Res Public Health* 2021;18:7610.
 26. Leitsalu L, Haller T, Esko T *et al.* Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int J Epidemiol* 2015;44:1137–47.
 27. Univerisity of Bergen. *TakeCare2020*. 2020. <https://www.uib.no/en/takecare2020> (29 March, 2021, date last accessed).
 28. Magnus P, Birke C, Vejrup K *et al.* Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol* 2016;45:382–88.
 29. Nilsen RM, Vollset SE, Gjessing HK *et al.* Self-selection and bias in a large prospective pregnancy cohort in Norway. *Paediatr Perinat Epidemiol* 2009;23:597–608.
 30. Smith BH, Campbell A, Linksted P *et al.* Cohort Profile: Generation Scotland: Scottish Family Health Study (GS: SFHS). The study, its participants and their potential for genetic research on health and illness. *Int J Epidemiol* 2013;42:689–700.
 31. Fawns-Ritchie C, Altschul D, Campbell A *et al.* CovidLife: a resource to understand mental health, well-being and behaviour during the COVID-19 pandemic in the UK [version 1; peer review: awaiting peer review]. *Wellcome Open Res* 2021;6:176.
 32. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606–13.
 33. Aluoja A, Shlik J, Vasar V, Luuk K, Leinsalu M. Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety. *Nord J Psychiatry* 1999;53:443–49.
 34. Ööpik P, Aluoja A, Kalda R, Maaros H-I. Screening for depression in primary care. *Fam Pract* 2006;23:693–98.
 35. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092–97.
 36. Eilertsen T, Hansén B, Kvale G, Abramowitz JS, Holm SE, Solem S. The dimensional obsessive-compulsive scale: development and validation of a short form (DOCS-SF). *Front Psychol* 2017;8:1503.
 37. Prins A, Bovin MJ, Smolenski DJ *et al.* The primary care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. *J Gen Intern Med* 2016;31:1206–11.
 38. Weathers FW, Litz BT, Herman DS, Huska JA, Keane TM. The PTSD Checklist (PCL): reliability, validity, and diagnostic utility. In: *Annual Convention of the International Society for Traumatic Stress Studies, October 1993*. San Antonio, TX, 1993, p. 462.
 39. Cohen S, Williamson, GS. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, Eds., *The Social Psychology of Health*. Saga Publications, Inc, 1988: 31–67.
 40. Eskildsen A, Dalgaard VL, Nielsen KJ *et al.* Cross-cultural adaptation and validation of the Danish consensus version of the 10-item Perceived Stress Scale. *Scand J Work Environ Health* 2015;41:486–90.
 41. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom Med* 1979;41:209–18.
 42. Hughes ME, Waite LJ, Hawkey LC, Cacioppo JT. A short scale for measuring loneliness in large surveys: results from two population-based studies. *Res Aging* 2004;26:655–72.
 43. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193–213.
 44. Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjørnevik M, Morin CM. A new scale for measuring insomnia: the Bergen Insomnia Scale. *Percept Mot Skills* 2008;107:691–706.
 45. Chalder T, Berelowitz G, Pawlikowska T *et al.* Development of a fatigue scale. *J Psychosom Res* 1993;37:147–153.
 46. Saffer BY, Lanting SC, Koehle MS, Klonsky ED, Iverson GL. Assessing cognitive impairment using PROMIS[®] applied cognition-abilities scales in a medical outpatient sample. *Psychiatry Res* 2015;226:169–72.
 47. Arias-de la Torre J, Vilagut G, Ronaldson A *et al.* Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. *Lancet Public Health* 2021;6:e729–38.
 48. Statistics Danmark. Folketal (*Population*). 2021. <https://www.dst.dk/da/Statistik/emner/befolkning-og-valg/befolkning-og-befolkningsfremskrivning/folketal> (August 2021, date last accessed).
 49. Statistics Iceland. *Population by Sex and Age 1841–2021*. 2021. https://px.hagstofa.is/pxen/pxweb/en/Ibuar/Ibuar_mannfjoldi_1_yfirlit_yfirlit_mannfjolda/MAN00101.px/table/tableViewLayout1/?rxid = 25fccf6d-ea97-49ad-9d9a-76087aa232c9 (27 August 2021, date last accessed).
 50. Statistics Estonia. *Rahvastik aasta alguses ja aastakeskmise rahvaarv soo ja vanuse järgi (Population at the beginning of the year and mean annual population by sex and age)*. 2021. https://andmed.stat.ee/et/stat/rahvastik_rahvastikunaita_jad-ja-koosseis_rahvaarv-ja-rahvastiku-koosseis/RV0212/table/tableViewLayout1 (27 August 2021, date last accessed).
 51. Statistics Danmark. 2021. *Befolkningens Højest Fuldførte Uddannelse (Highest completed educational level in the population)*. <https://www.dst.dk/da/Statistik/emner/uddannelse-og-viden/befolkningens-uddannelsesstatus/befolkningens-hoejst-fuldfoerte-uddannelse> (27 August 2021, date last accessed).

52. Statistics Iceland. *Educational Attainment of the Population by Levels According to ISCED 2011 2003–2019*. 2020. https://px.hagstofa.is/pxen/pxweb/en/Samfelag/Samfelag__skolamal__5__menntunarstada/SKO00007.px/?rxid = dce281ba-853e-4265-876e-9a151acc131b (27 August 2021, date last accessed).
53. Statistics Estonia. *Vähemalt 15 aastased hariduse, soo, vanusrühma ja maakonna järgi, 1. jaanuar (At least 15-year-old persons by education, sex, age group and country, 1 January (2012-2017))*. 2020. https://andmed.stat.ee/et/stat/rahvastik__rahvastikunaitajad-ja-koosseis__rahvaarv-ja-rahvastiku-koosseis/RV0231U/table/tableViewLayout1v (27 August 2021, date last accessed).
54. Statistics Sweden. *Population by Age and Sex. Year 1860–2020*. 2020. https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101A/BefolkningR1860N/ (27 August 2021, date last accessed).
55. StatBank Norway. *Population, by Sex and One-Year Age Groups 1986–2021*. 2021. <https://www.ssb.no/en/statbank/table/07459/> (27 August 2021, date last accessed).
56. Scotland's Census. *Population*. 2021. <https://www.scotlandscensus.gov.uk/census-results/at-a-glance/population> (27 August 2021, date last accessed).
57. Statistics Sweden. *Population 16–95+ Years of Age by Region, Level of Education, Age and Sex. Year 2008–2020*. 2020. https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__UF__UF0506/UtbBefRegionR/ (27 August 2021, date last accessed).
58. Statistics Norway. *Education*. 2021. <https://www.ssb.no/en/utdanning> (30 August 2021, date last accessed).
59. Scotland's Census. *Scottish Council Area 2011 by Highest Level of Qualification by Term-Time Address (Indicator) and Age*. 2013. <https://www.scotlandscensus.gov.uk/webapi/jsf/tableView/tableView.xhtml> (30 August 2021, date last accessed).